News

Virginia Medtech Company Is Awarded $13M Contract Continuation from the Navy

NIRSense Inc., headquartered in Richmond, Virginia, won an expansion to a competitively-awarded contract this month to build fieldable physiology monitors for the US Navy. NIRSense has been working with the Department of Defense since 2019 to build medical-grade physiology monitors to support US warfighter safety, performance, and medical care in training and operations. “NIRSense has developed unmatched capabilities to provide physiological monitoring in challenging environments faced by our soldiers, sailors, airmen and marines at the direction of Navy, Army, and Air Force stakeholders”, said NIRSense CEO Casey Boutwell, PhD. Future battlefields are expected to produce new challenges for the military health system requiring the DoD to look for new solutions in training safety and casualty care. Dr. Boutwell continued; “We are honored to be selected to contribute to the critical mission of safely training and caring for one of our nation’s most valuable assets, the American warfighter.”

The contract continuation was funded by Naval Medical Research Command-Naval Advanced Medical Development (NMRC-NAMD) through the Medical Technology Enterprise Consortium (MTEC). NIRSense is actively hiring design, engineering, and management talent in offices in Virginia and North Carolina.

Learn more here.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …